RESUMEN
The authors have added selenium tablets to the diet of 15 patients with malignant brain tumors. In twelve patients with glioblastoma multiforme this treatment didn't prolong the postoperative survival. Further clinical observations are necessary to precise the usefulness of selenium in cases of low-grade gliomas.
Asunto(s)
Astrocitoma/tratamiento farmacológico , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Cerebelosas/tratamiento farmacológico , Glioblastoma/tratamiento farmacológico , Meduloblastoma/tratamiento farmacológico , Selenio/administración & dosificación , Adulto , Astrocitoma/mortalidad , Astrocitoma/radioterapia , Astrocitoma/cirugía , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirugía , Neoplasias Cerebelosas/mortalidad , Neoplasias Cerebelosas/radioterapia , Neoplasias Cerebelosas/cirugía , Niño , Terapia Combinada , Irradiación Craneana , Femenino , Estudios de Seguimiento , Glioblastoma/mortalidad , Glioblastoma/radioterapia , Humanos , Masculino , Meduloblastoma/mortalidad , Meduloblastoma/radioterapia , Meduloblastoma/cirugía , Complicaciones Posoperatorias/mortalidad , Tasa de Supervivencia , Vitamina E/administración & dosificaciónRESUMEN
The concentrations of serum selenium were measured by atomic absorption spectrophotometry in 139 patients with tumors in cranium cavity. The data from patients were compared with those from a reference group of 294 healthy adult individuals. The serum concentrations of selenium is significantly decreased (p less than 0.001) in patients with malignant tumors. The authors discuss the possibilities for treatment of malignant tumours of central nervous system with selenium.